Simon Amy 4

What Happened

• Amy Simon, Chief Medical Officer of Beam Therapeutics (BEAM), received a derivative award on 2026-01-31 for 88,500 underlying shares. The reported acquisition price is $0.00, indicating an equity award (stock option) grant rather than an open-market purchase or sale. The grant itself has no immediate cash value shown on the Form 4.

Key Details

• Transaction date: 2026-01-31; Transaction type: Award/Grant (derivative).
• Shares involved: 88,500 underlying shares; reported price: $0.00 (grant).
• Shares owned after transaction: Not specified in the provided filing excerpt — see the full Form 4 for total beneficial ownership.
• Footnote: "This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with Beam Therapeutics Inc. through each vesting date."
• No late filing (timeliness) flag was provided in the supplied data.

Context

• This filing reports a grant of stock options (a derivative award). These options vest over four years in equal monthly installments and are not an immediate sale or purchase; they typically require continued service and a future exercise to convert to shares. Such grants are common as executive compensation and do not by themselves indicate buying or selling sentiment.